Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Acadia Pharma (ACAD) to stop pimavanserin trials after failure
March 12, 2024 12:52 PM EDTShares of Acadia Pharma (NASDAQ: ACAD) plunged Tuesday after the company reported after the close on Monday that its Phase 3 ADVANCE-2 trial did not meet its primary endpoint.
The company's stock price is down more than 15% at $20.48 per share following the news.
The Phase 3 ADVANCE-2 trial was... More
Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
March 12, 2024 4:51 AM EDTMizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 (from $39.00).
The analyst comments "Given the failed ADVANCE-2 trial, we remove our sales forecast for Nuplazid in negative symptoms of schizophrenia (NSS). With NSS... More
Acadia Pharma (ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint
March 11, 2024 4:10 PM EDTAcadia Pharma (NASDAQ: ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of... More